- Report
- April 2023
- 147 Pages
Global
From €4691EUR$4,949USD£3,919GBP
- Report
- February 2024
- 112 Pages
Global
From €4502EUR$4,750USD£3,761GBP
- Report
- June 2022
- 140 Pages
Global
From €4502EUR$4,750USD£3,761GBP
- Report
- November 2022
- 294 Pages
Global
From €3412EUR$3,600USD£2,851GBP
- Report
- August 2022
- 70 Pages
Middle East, Africa
From €1422EUR$1,500USD£1,188GBP
- Report
- December 2023
- 250 Pages
Global
€4734EUR$4,995USD£3,955GBP
- Report
- July 2022
- 109 Pages
Global
From €1896EUR$2,000USD£1,584GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
Dextroamphetamine is a central nervous system (CNS) stimulant drug used to treat attention deficit hyperactivity disorder (ADHD) and narcolepsy. It is also used off-label to treat depression, obesity, and other conditions. Dextroamphetamine works by increasing the activity of certain neurotransmitters in the brain, such as dopamine and norepinephrine, which can improve focus and alertness. It is available in both immediate-release and extended-release formulations. Common side effects include insomnia, dry mouth, and loss of appetite.
Dextroamphetamine is a widely prescribed CNS drug, with millions of prescriptions written each year. It is available in both generic and brand-name formulations, and is covered by most insurance plans. It is also available in combination with other drugs, such as amphetamine and lisdexamfetamine.
Some companies in the dextroamphetamine market include Shire Pharmaceuticals, Actavis, Teva Pharmaceuticals, and Mylan. Show Less Read more